Home | Sitemap | Search | ContactA- A A+
   
 
    Public Member Support us  
 

IBCSG 45-13 PANACEA 

A phase Ib/II trial evaluating the efficacy of MK-3475 and trastuzumab in patients with trastuzumab-resistant, HER2-positive metastatic breast cancers.

DESIGN

please click on the picture to see a larger version

Study Chair
Dr. Sherene Loi, Peter MacCallum Cander Center
Prof. Fabrice Andre, Institut Gustave Roussy

Trial Monitors
Daniela Celotto, Carmen Comune, Magdalena Sánchez-Hohl

IBCSG Coordinating Center, Bern, Switzerland
Phone: +41 31 511 94 00
Fax: +41 31 511 94 01
Email: panacea-monitoring@ibcsg.org

Lead Trial Coordinator
Holly Shaw

Statistician
Anita Giobbie-Hurder

Data Manager
Susan Fischer, Karolyn Scott

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: ibcsg45_Panacea@fstrf.org

Date of Activation
May 9, 2014

Targeted Accrual
between 6 and 61 patients


News

14.06.2020:
Save the date and join the IBCSG Pink Ladies! June 14, 2020

20.03.2020:
The next IBCSG Annual Meeting will take place in Barcelona Spain on March 20 and 21, 2020.       

11.11.2019:
New publications are available 

All News

 
  Print